scholarly journals Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis

2016 ◽  
Vol 64 (3) ◽  
pp. 543-552 ◽  
Author(s):  
Alan J. Sinclair ◽  
Bruce Bode ◽  
Stewart Harris ◽  
Ujjwala Vijapurkar ◽  
Wayne Shaw ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Pooled Analysis ◽  
Efficacy And Safety

scholarly journals Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials

2014 ◽  
Vol 2 (1) ◽  
pp. e000020 ◽  
Author(s):  
Jaime A Davidson ◽  
Rosemarie Lajara ◽  
Richard B Aguilar ◽  
Michaela Mattheus ◽  
Hans-Juergen Woerle ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Pooled Analysis ◽  
Efficacy And Safety ◽  
Phase 3

scholarly journals Efficacy and Safety of Canagliflozin in Patients With Type 2 Diabetes Mellitus of Different Ethnicity

2016 ◽  
Vol 26 (2) ◽  
pp. 221 ◽  
Author(s):  
Jaime A. Davidson ◽  
Richard Auilar ◽  
Fernando J. Lavalle Gonzalez ◽  
Angelina Trujillo ◽  
Maria Alba ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Sglt2 Inhibitor ◽  
Pooled Analysis ◽  
Efficacy And Safety ◽  
Latino Women ◽  
Post Hoc ◽  
Mycotic Infections

<p><strong>Objective</strong>: To assess the efficacy and safety of the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin in patients of different ethnicities.</p><p><strong>Design, Setting, and Patients:</strong> Post hoc analysis of data pooled from four randomized, placebo-controlled, phase 3 studies of adults with inadequately controlled type 2 diabetes mellitus (T2DM).</p><p><strong>Interventions:</strong> Once daily oral canagliflozin 100 mg or 300 mg, or placebo.</p><p><strong>Main Outcome Measures:</strong> Efficacy endpoints included change from baseline in HbA1c, body weight (BW), systolic blood pressure (SBP), and lipids at week 26; safety and tolerability were assessed by adverse event reports.</p><p><strong>Results:</strong> Of the 2,313 patients included in this pooled analysis, 609 self-identified as Hispanic/Latino. Hispanic/Latino patients had a mean age of 54 years, mean duration of T2DM of 7 years, mean HbA1c of 8.1%, mean body mass index of 31.2 kg/m2, and mean SBP of 126.1 mm Hg. There were more women in the non-Hispanic/Latino cohort (63%) compared with the Hispanic/ Latino cohort. Placebo-subtracted changes in HbA1c were −.82% with canagliflozin 100 mg and −.94% with canagliflozin 300 mg in the Hispanic/Latino cohort, which were similar to reductions observed in the non-Hispanic/Latino cohort. Significantly greater dose-related reductions in HbA1c, BW, and SBP were observed with both canagliflozin doses compared with placebo. Canagliflozin was generally well-tolerated. Genital mycotic infections were less frequent in Hispanic/Latino women than in non-Hispanic/Latino women.</p><p><strong>Conclusions:</strong> The SGLT2 inhibitor canagliflozin was generally well-tolerated and was associated with clinically meaningful reductions in HbA1c, BW, and SBP in both Hispanic/Latino and non-Hispanic/ Latino patients with T2DM. <em>Ethn Dis.</em> 2016;26(1):221-228; doi:10.18865/ ed.26.2.221</p>

Long-Term Efficacy and Safety of Ertugliflozin in Patients (Pts) with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin (MET) Monotherapy—104-Week VERTIS MET Trial

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1129-P
Author(s):  
SILVINA GALLO ◽  
BERNARD CHARBONNEL ◽  
ALLISON GOLDMAN ◽  
HARRY SHI ◽  
SUSAN HUYCK ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Efficacy And Safety ◽  
Term Efficacy

Efficacy and Safety of Continuing Sitagliptin when Initiating Insulin Therapy in Subjects with Type 2 Diabetes Mellitus

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 112-LB ◽  
Author(s):  
RONAN ROUSSEL ◽  
SANTIAGO DURAN-GARCIA ◽  
YILONG ZHANG ◽  
SUNERI SHAH ◽  
CAROLYN DARMIENTO ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Therapy ◽  
Efficacy And Safety

Efficacy and Safety of Evolocumab in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia or Mixed Dyslipidemia

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 128-OR ◽  
Author(s):  
ROBERT S. ROSENSON ◽  
MARTHA L. DAVIGLUS ◽  
PETER REAVEN ◽  
PAOLO POZZILLI ◽  
HAROLD BAYS ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Efficacy And Safety ◽  
Mixed Dyslipidemia
Sign in / Sign up

Export Citation Format

Share Document